These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26692095)

  • 41. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
    N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
    Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
    Goel B; Tripathi N; Bhardwaj N; Jain SK
    Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
    Whittaker SR; Mallinger A; Workman P; Clarke PA
    Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
    Fischer PM
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
    Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
    Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell Cycle Regulation in Treatment of Breast Cancer.
    Cai Z; Liu Q
    Adv Exp Med Biol; 2017; 1026():251-270. PubMed ID: 29282688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
    Balakrishnan A; Vyas A; Deshpande K; Vyas D
    World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent advances on CDK inhibitors: An insight by means of in silico methods.
    Tutone M; Almerico AM
    Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications.
    Sofi S; Mehraj U; Qayoom H; Aisha S; Asdaq SMB; Almilaibary A; Mir MA
    Med Oncol; 2022 Apr; 39(6):106. PubMed ID: 35486263
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers.
    Mikhail S; Albanese C; Pishvaian MJ
    Am J Pathol; 2015 May; 185(5):1185-97. PubMed ID: 25747534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics.
    Stone A; Sutherland RL; Musgrove EA
    Crit Rev Oncog; 2012; 17(2):175-98. PubMed ID: 22471707
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dinaciclib for the treatment of breast cancer.
    Criscitiello C; Viale G; Esposito A; Curigliano G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1305-12. PubMed ID: 25107301
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic targeting of transcriptional cyclin-dependent kinases.
    Galbraith MD; Bender H; Espinosa JM
    Transcription; 2019 Apr; 10(2):118-136. PubMed ID: 30409083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy.
    Liu Y; Fu L; Wu J; Liu M; Wang G; Liu B; Zhang L
    Eur J Med Chem; 2022 Feb; 229():114056. PubMed ID: 34942431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the cell cycle in breast cancer: towards the next phase.
    Thu KL; Soria-Bretones I; Mak TW; Cescon DW
    Cell Cycle; 2018; 17(15):1871-1885. PubMed ID: 30078354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
    Jorda R; Hendrychová D; Voller J; Řezníčková E; Gucký T; Kryštof V
    J Med Chem; 2018 Oct; 61(20):9105-9120. PubMed ID: 30234987
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical anticancer drug development: targeting the cyclin-dependent kinases.
    Benson C; Kaye S; Workman P; Garrett M; Walton M; de Bono J
    Br J Cancer; 2005 Jan; 92(1):7-12. PubMed ID: 15558073
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bioprobes for investigating mammalian cell cycle control.
    Osada H
    J Antibiot (Tokyo); 1998 Nov; 51(11):973-82. PubMed ID: 9918389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.